IL213923A - Annotated 6 - {[(azididine / pyrrolidine) -1-yl] alkyl} -5,1-dihydro-h4-pyrazolo [4,3– d] pyrimidine-4-on and pharmaceutical preparations containing them - Google Patents
Annotated 6 - {[(azididine / pyrrolidine) -1-yl] alkyl} -5,1-dihydro-h4-pyrazolo [4,3– d] pyrimidine-4-on and pharmaceutical preparations containing themInfo
- Publication number
- IL213923A IL213923A IL213923A IL21392311A IL213923A IL 213923 A IL213923 A IL 213923A IL 213923 A IL213923 A IL 213923A IL 21392311 A IL21392311 A IL 21392311A IL 213923 A IL213923 A IL 213923A
- Authority
- IL
- Israel
- Prior art keywords
- azetidin
- pyrazolo
- pyrrolidin
- pyrimidin
- dihydro
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 title 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20609209P | 2009-01-26 | 2009-01-26 | |
| PCT/IB2010/050133 WO2010084438A1 (en) | 2009-01-26 | 2010-01-13 | Amino-heterocyclic compounds used as pde9 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL213923A0 IL213923A0 (en) | 2011-07-31 |
| IL213923A true IL213923A (en) | 2016-08-31 |
Family
ID=42062324
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL213923A IL213923A (en) | 2009-01-26 | 2011-07-04 | Annotated 6 - {[(azididine / pyrrolidine) -1-yl] alkyl} -5,1-dihydro-h4-pyrazolo [4,3– d] pyrimidine-4-on and pharmaceutical preparations containing them |
| IL246882A IL246882A0 (en) | 2009-01-26 | 2016-07-21 | Amino-heterocyclic compounds used as pde9 inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL246882A IL246882A0 (en) | 2009-01-26 | 2016-07-21 | Amino-heterocyclic compounds used as pde9 inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8278295B2 (https=) |
| EP (1) | EP2389382B1 (https=) |
| JP (1) | JP5656874B2 (https=) |
| KR (1) | KR101417237B1 (https=) |
| CN (1) | CN102292340B (https=) |
| AR (1) | AR074966A1 (https=) |
| AU (1) | AU2010207507B2 (https=) |
| CA (1) | CA2748864C (https=) |
| DK (1) | DK2389382T3 (https=) |
| ES (1) | ES2420860T3 (https=) |
| HR (1) | HRP20130530T1 (https=) |
| IL (2) | IL213923A (https=) |
| MX (1) | MX2011007862A (https=) |
| PL (1) | PL2389382T3 (https=) |
| PT (1) | PT2389382E (https=) |
| SG (1) | SG172805A1 (https=) |
| SI (1) | SI2389382T1 (https=) |
| TW (1) | TWI404721B (https=) |
| UY (1) | UY32391A (https=) |
| WO (1) | WO2010084438A1 (https=) |
| ZA (1) | ZA201105931B (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| LT2889033T (lt) | 2008-11-19 | 2018-07-10 | Forum Pharmaceuticals Inc. | Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis |
| JP5808319B2 (ja) * | 2009-05-11 | 2015-11-10 | フォルム ファーマシューティカルズ、インコーポレイテッド | アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療 |
| PE20170923A1 (es) | 2010-05-17 | 2017-07-12 | Forum Pharmaceuticals Inc | Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidratado |
| KR20130097178A (ko) | 2010-09-07 | 2013-09-02 | 아스텔라스세이야쿠 가부시키가이샤 | 퀴녹살린 화합물 |
| RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
| BR112015007731B1 (pt) | 2011-10-10 | 2022-05-31 | H. Lundbeck A/S | Composto, composição farmacêutica que o compreende e uso do mesmo |
| BR112014018199A8 (pt) | 2012-01-26 | 2021-03-02 | H Lundbeck As | inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| EP3461481A1 (en) | 2012-05-08 | 2019-04-03 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
| WO2014024125A1 (en) | 2012-08-08 | 2014-02-13 | Celon Pharma S.A. | Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors |
| TW201410244A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| WO2014063105A1 (en) * | 2012-10-19 | 2014-04-24 | Celus Pharmaceuticals, Inc. | Vitamin d analogues for the treatment of a neurological disorder |
| CN103207246B (zh) * | 2012-12-21 | 2017-10-10 | 北京万全德众医药生物技术有限公司 | 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法 |
| EP3139924A4 (en) * | 2014-05-06 | 2018-03-07 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| RU2017107521A (ru) | 2014-08-27 | 2018-10-01 | Ф. Хоффманн-Ля Рош Аг | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| PT3865484T (pt) | 2015-07-07 | 2024-01-30 | H Lundbeck As | Inibidor da pde9 com esqueleto de imidazo pirazinona para tratamento de doenças periféricas |
| US10376504B2 (en) | 2015-07-29 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Substituted quinolinones as PDE9 inhibitors |
| WO2017019724A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Phenyl-cyanoquinolinone pde9 inhibitors |
| WO2017019726A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Oxy-cyanoquinolinone pde9 inhibitors |
| JP6983161B2 (ja) | 2015-09-15 | 2021-12-17 | プラクシス・バイオリサーチ・エルエルシー | フェンカンファミンのプロドラッグ |
| CN105467028A (zh) * | 2015-11-18 | 2016-04-06 | 北京万全德众医药生物技术有限公司 | 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法 |
| CN105669680B (zh) * | 2016-03-24 | 2018-02-23 | 南京药捷安康生物科技有限公司 | 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| MX2018016127A (es) | 2016-07-06 | 2019-05-30 | Imara Inc | Inhibidores de pde9 para el tratamiento de enfermedades perifericas. |
| WO2018073251A1 (en) * | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
| WO2018078042A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising administration of imidazopyrazinones |
| AU2017350473A1 (en) | 2016-10-28 | 2019-04-18 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
| EP3541784B1 (en) | 2016-11-18 | 2023-09-13 | Integrative Research Laboratories Sweden AB | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
| KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
| JP7053645B2 (ja) * | 2017-02-23 | 2022-04-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 化合物ｉｉｉの新しい医学的使用 |
| CN106957300A (zh) * | 2017-04-12 | 2017-07-18 | 苏州汉德创宏生化科技有限公司 | 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法 |
| MX2019013626A (es) | 2017-05-22 | 2020-01-13 | Topadur Pharma Ag | Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos. |
| CN115746003B (zh) * | 2017-05-26 | 2024-08-09 | 卡都瑞恩医药公司 | 制备和使用pde9抑制剂的方法 |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| KR20200010220A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 피라졸로퀴놀린 유도체를 함유하는 루이소체 질병 치료제 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| SG10202113199RA (en) * | 2017-06-01 | 2021-12-30 | Eisai R&D Man Co Ltd | Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine |
| AU2018281131B2 (en) | 2017-06-08 | 2022-01-20 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine PDE9 inhibitors |
| DK3717488T3 (da) | 2017-11-27 | 2021-12-13 | Dart Neuroscience Llc | Substituerede furanopyrimidinforbindelser som pde1-inhibitorer |
| CA3100988A1 (en) | 2018-05-25 | 2019-11-28 | Imara Inc. | Monohydrate and crystalline forms of 6-[(3s,4s)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one |
| CA3110680A1 (en) | 2018-08-31 | 2020-03-05 | Imara Inc. | Pde9 inhibitors for treating sickle cell disease |
| WO2020182076A1 (zh) * | 2019-03-08 | 2020-09-17 | 南京药捷安康生物科技有限公司 | 磷酸二酯酶抑制剂的用途 |
| EP4003342A1 (en) * | 2019-07-29 | 2022-06-01 | Constellation Pharmaceuticals, Inc. | Compounds for use in treating neurological disorders |
| CN120897742A (zh) * | 2022-11-15 | 2025-11-04 | 福睿德姆生物科学公司 | 通过抑制9型磷酸二酯酶增强血清素能致幻药物在治疗或预防某些神经精神障碍中的功效 |
| AU2024326748A1 (en) * | 2023-08-18 | 2026-04-02 | Katholieke Universiteit Leuven | 1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and/or autoimmune diseases |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1177960A (zh) * | 1995-03-10 | 1998-04-01 | 圣诺菲药品有限公司 | 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法 |
| GB9722520D0 (en) * | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| JP2005508978A (ja) | 2001-11-02 | 2005-04-07 | ファイザー・プロダクツ・インク | Ｐｄｅ９阻害薬によるインスリン抵抗性症候群及び２型糖尿病の治療 |
| US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| SE0103795D0 (sv) | 2001-11-02 | 2001-11-02 | Astrazeneca Ab | Compounds and method for the treatment of överactive bladder |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| WO2003049527A2 (en) * | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| RS52166B (sr) * | 2007-05-11 | 2012-08-31 | Pfizer Inc. | Amino-heterociklična jedinjenja |
| UA105362C2 (en) * | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
-
2009
- 2009-12-31 TW TW098146481A patent/TWI404721B/zh not_active IP Right Cessation
-
2010
- 2010-01-13 KR KR1020117019758A patent/KR101417237B1/ko not_active Expired - Fee Related
- 2010-01-13 EP EP10701921.8A patent/EP2389382B1/en not_active Not-in-force
- 2010-01-13 JP JP2011547011A patent/JP5656874B2/ja not_active Expired - Fee Related
- 2010-01-13 AU AU2010207507A patent/AU2010207507B2/en not_active Ceased
- 2010-01-13 DK DK10701921.8T patent/DK2389382T3/da active
- 2010-01-13 SG SG2011047594A patent/SG172805A1/en unknown
- 2010-01-13 CN CN201080005394.XA patent/CN102292340B/zh not_active Expired - Fee Related
- 2010-01-13 SI SI201030250T patent/SI2389382T1/sl unknown
- 2010-01-13 PL PL10701921T patent/PL2389382T3/pl unknown
- 2010-01-13 HR HRP20130530AT patent/HRP20130530T1/hr unknown
- 2010-01-13 CA CA2748864A patent/CA2748864C/en not_active Expired - Fee Related
- 2010-01-13 PT PT107019218T patent/PT2389382E/pt unknown
- 2010-01-13 ES ES10701921T patent/ES2420860T3/es active Active
- 2010-01-13 MX MX2011007862A patent/MX2011007862A/es active IP Right Grant
- 2010-01-13 WO PCT/IB2010/050133 patent/WO2010084438A1/en not_active Ceased
- 2010-01-25 UY UY0001032391A patent/UY32391A/es not_active Application Discontinuation
- 2010-01-25 AR ARP100100153A patent/AR074966A1/es unknown
- 2010-01-26 US US12/693,480 patent/US8278295B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 IL IL213923A patent/IL213923A/en not_active IP Right Cessation
- 2011-08-12 ZA ZA2011/05931A patent/ZA201105931B/en unknown
-
2012
- 2012-08-31 US US13/600,522 patent/US8618117B2/en not_active Expired - Fee Related
-
2013
- 2013-11-27 US US14/091,404 patent/US20140088081A1/en not_active Abandoned
-
2016
- 2016-07-21 IL IL246882A patent/IL246882A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL213923A (en) | Annotated 6 - {[(azididine / pyrrolidine) -1-yl] alkyl} -5,1-dihydro-h4-pyrazolo [4,3– d] pyrimidine-4-on and pharmaceutical preparations containing them | |
| HUS2400038I1 (hu) | Pirrolo[2,3-d]primidin származékok, mint protein kináz B inhibitorok | |
| IL219424A (en) | Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors | |
| IL211136A0 (en) | Pyrido [5,4-d] pyrimidines as cell proliferation inhibitors | |
| SI2300478T1 (sl) | 1-heterociklil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onski derivati in njihova uporaba kot PDE9A modulatorji | |
| IL214436A0 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
| IN2012DN02577A (https=) | ||
| IL217798A0 (en) | Pyrrolo [1,2-b]pyridazine derivatives as janus kinase inhibitors | |
| PL2419428T3 (pl) | Pochodne imidazo[1,2-A]pirydyny jako inhibitory kinaz FGFR do zastosowania w terapii | |
| IL229606A0 (en) | Pyrazolone [3, 4-d] pyrimidine compounds and their use as 2pde inhibitors and/or 4a3 cyp inhibitors | |
| IL198675A0 (en) | Novel aminopyrimidine derivatives as plk1 inhibitors | |
| AP2012006631A0 (en) | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors | |
| IL217414A0 (en) | SUBSTITUTED PYRAZOLO[1, 5-a] PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS | |
| IL220432A (en) | History of theo [b – 3,2] pyridinedione and pharmaceutical preparations containing them | |
| ZA201100429B (en) | Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors | |
| IL210074A0 (en) | Compositions with and process for methylmorpholin-substituted pyrido[2,3-d]pyrimidines | |
| IL219371A (en) | Ethylene History - (s-Triazolo / Pyrzolo) [a – 5,1] (Pyridine / Pyrimidine) and Pharmaceuticals Containing Them | |
| IL212716A0 (en) | Thieno [3,2-c] pyridine derivatives as kinase inhibitors for use in the treatment of cancer | |
| SI2124944T1 (sl) | Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze | |
| IL205510A0 (en) | Benzimidazoledihydrothiadiazinone derivatives as fructose - 1, 6 - bisphosphatase inhibitors, and pharmaceutical compositions comprising same | |
| SG10201403149YA (en) | Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof | |
| IL213589A0 (en) | DIPYRIDO [2,3-d;4-d] PYRROL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| IL212942A (en) | History of Rifamycin, Methods of Preparation, Pharmaceutical Preparations Containing Them and Their Uses | |
| ZA201104945B (en) | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | |
| ZA201107883B (en) | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containint these derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |